Connect with Us:
Join our Investment Community over over 14,000: https://thewealthelevator.com/club
For Holistic Wellness and Performance Coaching: connect with Dr. Po at drpowu.com
The hosts discuss GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro—originally diabetes drugs that mimic a natural gut hormone to increase satiety, slow gastric emptying, reduce appetite signaling via the brain, and improve glucose control—now widely used for weight loss. They cite trials showing roughly 15–20% body-weight loss over about 68–72 weeks and note cardiovascular risk reductions in high-risk groups. Key downsides include loss of muscle mass if protein and resistance training aren’t prioritized, common GI side effects, rare serious risks like pancreatitis or gallbladder issues, uncertain long-term outcomes (including rodent thyroid findings not yet seen in humans), cost/insurance hurdles, and weight regain after stopping—raising whether it’s a bridge or chronic therapy. They also cover identity and “cognitive bandwidth” benefits from reduced food chatter, and close with practical takeaways: clarify goals, train and eat intentionally, plan maintenance, and adopt a healthy narrative about using tools as leverage.
00:00 GLP-1 Hype Begins
01:26 What GLP-1 Actually Is
03:31 Food Addiction Angle
04:26 Results From Trials
06:08 Downsides Muscle Loss
07:11 Shortcut Debate Ethics
10:53 Cost Access Insurance
11:25 Side Effects Regain Risks
13:38 Identity Self Image
15:17 Upsides Prevention Momentum
16:19 Other Peptides Cancer Talk
17:33 Long Term Safety Unknowns
18:32 Self Driving Data Analogy
19:03 Food Noise Mental Relief
20:08 Fasting Labs No One Size
21:40 Momentum Confidence Spillover
23:18 Urges Addiction Parallels
25:08 Bridge Versus Lifelong Use
25:51 Leverage And Healthy Friction
27:55 Dosing Half Life Cycling
30:44 Practical GLP1 Takeaways
33:25 Kindness And Closing Thoughts
","author_name":"Lane Kawaoka, PE & Dr. Po Wu"}